Agreement
Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents
DIJON, France, May 15, 2024–(BUSINESS WIRE)–Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of Precision Medicine applications based on the Affilin® technology platform, […]
Atossa Therapeutics Announces Expanded Research Agreement
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drugs conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need […]
Menarini Group and Insilico Medicine sign exclusive global license agreement for …
Florence, Italy and New York (ots/PRNewswire) KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, one of the most common subtypes. The molecule showed high preclinical activity. Insilico presented data on this new molecule at the […]
Menarini Group and Insilico Medicine sign exclusive global license agreement for …
Florence, Italy and New York (ots/PRNewswire) KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, one of the most common subtypes. The molecule showed high preclinical activity. Insilico presented data on this new molecule at the […]
Menarini Group and Insilico Medicine enter into exclusive global license agreement for new KAT6 inhibitor for potential treatment of breast cancer and other oncology indications USA – Deutsch Italia – Italiano APAC – Traditional Chinese USA – español Latin America – español USA – English USA – English
KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, one of the most common subtypes. The molecule showed high preclinical activity. Insilico presented data on this new molecule at the San Antonio Breast Cancer Symposium in […]